Abiopharma

Pfizer Inc. - Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Johnson & Johnson - RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Integer Holdings Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Integer Holdings Corporation - ITGR

New Form SCHEDULE 13D/A - Ventyx Biosciences, Inc. Filed: 2026-01-09 AccNo: 0000929638-26-000112 Size: 15 KB

New Form SCHEDULE 13D/A - Ventyx Biosciences, Inc. Filed: 2026-01-09 AccNo: 0001193125-26-009348 Size: 12 KB

VR Announces Further Upsize of Brokered Private Placement Led by Centurion One Capital to $2,750,000

Director Gilboa David Abraham 🟡 adjusted position in 1.8M shares (3 derivative) of Warby Parker Inc. (WRBY) at $29.09 ($2.6M) Transaction Date: Jan 07, 2026 | Filing ID: 002586

Director Blumenthal Neil Harris 🟡 adjusted position in 4.2M shares (7 derivative) of Warby Parker Inc. (WRBY) at $27.08 ($1.4M) Transaction Date: Jan 07, 2026 | Filing ID: 002584

Vultaggio Vincent 🟢 acquired 100.0K shares (1 derivative) of Zentalis Pharmaceuticals, Inc. (ZNTL) at $2.84 Transaction Date: Jan 08, 2026 | Filing ID: 000002

Bucher James B 🟢 acquired 100.0K shares (1 derivative) of Zentalis Pharmaceuticals, Inc. (ZNTL) at $2.84 Transaction Date: Jan 08, 2026 | Filing ID: 000003

Bruns Ingmar 🟢 acquired 365.0K shares (1 derivative) of Zentalis Pharmaceuticals, Inc. (ZNTL) at $2.84 ($1.0M) Transaction Date: Jan 08, 2026 | Filing ID: 000002

Director EASTLAND JULIA MARIE 🟢 acquired 775.0K shares (1 derivative) of Zentalis Pharmaceuticals, Inc. (ZNTL) at $2.84 ($2.2M) Transaction Date: Jan 08, 2026 | Filing ID: 000002